China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results

PR Newswire
TAI'AN, Shandong, China
Nov 9, 2010

TAI'AN, Shandong, China, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will host a conference call at 9:00 a.m. EST on Tuesday, November 16, 2010, to discuss the third quarter 2010 financial results.

Hosting the call will be Mr. Colin Zhao, Chief Executive Officer, and Mr. Tristan Kuo, Chief Financial Officer. The Company plans to distribute its earnings press release prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 877-409-5468. International callers should dial +1-702-894-2400. The pass code for the call is 23890623.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Tuesday, November 16, 2010 at 11:00 a.m. EST. To access the replay, dial 800-642-1687, international callers should dial +1-706-645-9291. The conference pass code is 23890623.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.


    Company Contact:                         Investor Relations Contact:
                  Mr. Ming Yin               Mr. Crocker Coulson, President
            Vice President - Finance         CCG Investor Relations
         China Biologic Products, Inc.       Phone: +1-646-213-1915
              Tel: +86-851-3605846           Email: crocker.coulson@ccgir.com
          Email: IR@chinabiologic.com        www.ccgirasia.com
             www.chinabiologic.com

SOURCE China Biologic Products, Inc.

SOURCE: China Biologic Products, Inc.

China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results

PR Newswire

TAI'AN, Shandong, China, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will host a conference call at 9:00 a.m. EST on Tuesday, November 16, 2010, to discuss the third quarter 2010 financial results.  

Hosting the call will be Mr. Colin Zhao, Chief Executive Officer, and Mr. Tristan Kuo, Chief Financial Officer. The Company plans to distribute its earnings press release prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 877-409-5468. International callers should dial +1-702-894-2400. The pass code for the call is 23890623.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Tuesday, November 16, 2010 at 11:00 a.m. EST. To access the replay, dial 800-642-1687, international callers should dial +1-706-645-9291. The conference pass code is 23890623.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

Company Contact:

Investor Relations Contact:

Mr. Ming Yin

Mr. Crocker Coulson, President

Vice President - Finance

CCG Investor Relations

China Biologic Products, Inc.

Phone: +1-646-213-1915

Tel: +86-851-3605846

Email: crocker.coulson@ccgir.com

Email: IR@chinabiologic.com

www.ccgirasia.com

www.chinabiologic.com




SOURCE China Biologic Products, Inc.

CONTACT: Mr. Ming Yin, Vice President - Finance of China Biologic Products, Inc., +86-851-3605846, or IR@chinabiologic.com; or Mr. Crocker Coulson, President of CCG Investor Relations, +1-646-213-1915, or crocker.coulson@ccgir.com

Web Site: http://www.chinabiologic.com